Health TrialsbyHealthPanel

Chongqing Primary Aldosteronism Study

ConditionPrimary Aldosteronism
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorChongqing Medical University

About this trial

We intends to conduct a series of original clinical research about PA, and establish a large cohort of PA and essential hypertension patients with long-term follow-up of cardiovascular events, renal end points etc. We will establish a large sample of blood, urine, adrenal tissue of the subjects, and the genomics,metabonomics, proteomics database, to explore the mechanism of the PA and target organ damage, risk factors, diagnostic methods and biomarkers.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

hypertensive patients who completed ARR screening and necessary further tests;

Voluntary to sign the informed consent.

Disqualifiers

patients with severe cardiac, hepatic or renal dysfunction;

suspicious or confirmed other types of secondary hypertension, including Cushing's syndrome, pheochromocytoma and renal artery stenosis et al.

Trial population

hypertensive patients who completed ARR screening and necessary further tests and Voluntary to be followed up will be included.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • no intervention

    Other intervention

    no intervention

Treatment groups

1,500 Participants
are divided into 2 treatment groups
Group A: Primary aldosteronism1 intervention
Group B: Essential hypertension1 intervention

Trial outcomes

Primary outcomes

1

numbers of patients who develop cardiovascular events

compare the long-term cardiovascular and cerebrovascular events in patients with primary aldosteronism and essential hypertension

Time frame
1-15 years

Secondary outcomes

1

estimated glomerular filtration rate (eGFR)

Compare the incidence of hypertensive nephropathy between two groups (based on eGFR)

Time frame
1-15 years
2

The incidence of new atrial fibrillation

Compare the occurrence of new atrial fibrillation between patients with primary aldosteronism and essential hypertension

Time frame
1-15 years
3

The incidence of left ventricular hypertrophy

Compare the occurrence of left ventricular hypertrophy between patients with primary aldosteronism and essential hypertension

Time frame
1-15 years
4

the variation of carotid intima-media thickness

Compare the occurrence of the variation of carotid intima-media thickness between patients with primary aldosteronism and essential hypertension

Time frame
1-15 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chongqing Medical University

Lead sponsor

First Affiliated Hospital of Chongqing Medical University

Sponsor institution

Source ClinicalTrials.gov
Apply now